Oral Treatment of Spontaneously Hypertensive Rats with Captopril-Surface Functionalized Furosemide-Loaded Multi-Wall Lipid-Core Nanocapsules

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2020 Jan 23

PMID 31963659

Citations 6

Authors

Cecilia B Michalowski

Marcelo D Arbo

Louise Altknecht

Andreia N Anciuti

Angelica S G Abreu

Luciana M R Alencar

Adriana R Pohlmann

Solange C Garcia

Silvia S Guterres

Affiliations

Soon will be listed here.

Abstract

Multi-wall lipid-core nanocapsule (MLNC) functionalized with captopril and nanoencapsulating furosemide within the core was developed as a liquid formulation for oral administration. The nanocapsules had mean particle size below 200 nm, showing unimodal and narrow size distributions with moderate dispersity (laser diffraction and dynamic light scattering). Zeta potential was inverted from -14.3 mV [LNC-Fur(0,5)] to +18.3 mV after chitosan coating. Transmission electron microscopy and atomic force microscopy showed spherical structures corroborating the nanometric diameter of the nanocapsules. Regarding the systolic pressure, on the first day, the formulations showed antihypertensive effect and a longer effect than the respective drug solutions. When both drugs were associated, the anti-hypertensive effect was prolonged. On the fifth day, a time effect reduction was observed for all treatments, except for the nanocapsule formulation containing both drugs [Capt(0.5)-Zn(25)-MLNC-Fur(0.45)]. For diastolic pressure, only Capt(0.5)-Zn(25)-MLNC-Fur(0.45) presented a significant difference ( < 0.05) on the first day. On the fifth day, both Capt(0.5)-MLNC-Fur(0.45) and Capt(0.5)-Zn(25)-MLNC-Fur(0.45) had an effect lasting up to 24 h. The analysis of early kidney damage marker showed a potential protection in renal function by Capt(0.5)-Zn(25)-MLNC-Fur(0.45). In conclusion, the formulation Capt(0.5)-Zn(25)-MLNC-Fur(0.45) proved to be suitable for hypertension treatment envisaging an important innovation.

Citing Articles

Optimization, physicochemical stability and in vivo study of alginate-chitosan composites as nanocarriers for low molecular weight angiotensin I-converting enzyme (ACE)-inhibitory peptide.

Auwal S, Ghanisma S, Saari N J Food Drug Anal. 2024; 32(3):358-370.

PMID: 39636769 PMC: 11464040. DOI: 10.38212/2224-6614.3522.

Nanoparticle-Based Therapies in Hypertension.

Story D, Aminoroaya A, Skelton Z, Kumari M, Zhang Y, Smith B Hypertension. 2023; 80(12):2506-2514.

PMID: 37767725 PMC: 10651274. DOI: 10.1161/HYPERTENSIONAHA.123.19523.

Role of Organic and Inorganic Nanoparticles in the Drug Delivery System for Hypertension Treatment: A Systematic Review.

Moradifar N, Kiani A, Veiskaramian A, Karami K Curr Cardiol Rev. 2022; 18(1):e110621194025.

PMID: 35297343 PMC: 9241118. DOI: 10.2174/1573403X17666210611115823.

Design of Olmesartan Medoxomil-Loaded Nanosponges for Hypertension and Lung Cancer Treatments.

Almutairy B, Alshetaili A, Alali A, Ahmed M, Anwer M, Aboudzadeh M Polymers (Basel). 2021; 13(14).

PMID: 34301030 PMC: 8309359. DOI: 10.3390/polym13142272.

Development and Validation of an Automated Zone Fluidics-Based Sensor for In Vitro Dissolution Studies of Captopril Using Total Error Concept.

Karakosta T, Tzanavaras P, Zacharis C Molecules. 2021; 26(4).

PMID: 33562585 PMC: 7914990. DOI: 10.3390/molecules26040824.

References

Joseph E, Saha R . Investigations on pharmacokinetics and biodistribution of polymeric and solid lipid nanoparticulate systems of atypical antipsychotic drug: effect of material used and surface modification. Drug Dev Ind Pharm. 2017; 43(4):678-686. DOI: 10.1080/03639045.2016.1278014. View

Bender E, Cavalcante M, Adorne M, Colome L, Guterres S, Abdalla D . New strategy to surface functionalization of polymeric nanoparticles: one-pot synthesis of scFv anti-LDL(-)-functionalized nanocapsules. Pharm Res. 2014; 31(11):2975-87. DOI: 10.1007/s11095-014-1392-5. View

Rao K, Reddy M, Horning J, Labhasetwar V . TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs. Biomaterials. 2008; 29(33):4429-38. PMC: 2570783. DOI: 10.1016/j.biomaterials.2008.08.004. View

Zhang G, Gao J, Qian J, Zhang L, Zheng K, Zhong K . Hydroxylated Mesoporous Nanosilica Coated by Polyethylenimine Coupled with Gadolinium and Folic Acid: A Tumor-Targeted T(1) Magnetic Resonance Contrast Agent and Drug Delivery System. ACS Appl Mater Interfaces. 2015; 7(26):14192-200. DOI: 10.1021/acsami.5b04294. View

Grotto D, Santa Maria L, Boeira S, Valentini J, Charao M, Moro A . Rapid quantification of malondialdehyde in plasma by high performance liquid chromatography-visible detection. J Pharm Biomed Anal. 2006; 43(2):619-24. DOI: 10.1016/j.jpba.2006.07.030. View

de Azevedo M, Tasic L, Fattori J, Rodrigues F, Cantos F, Ribeiro L . New formulation of an old drug in hypertension treatment: the sustained release of captopril from cyclodextrin nanoparticles. Int J Nanomedicine. 2011; 6:1005-16. PMC: 3124386. DOI: 10.2147/IJN.S18999. View

Nkansah P, Antipas A, Lu Y, Varma M, Rotter C, Rago B . Development and evaluation of novel solid nanodispersion system for oral delivery of poorly water-soluble drugs. J Control Release. 2013; 169(1-2):150-61. DOI: 10.1016/j.jconrel.2013.03.032. View

Saveyn H, De Baets B, Thas O, Hole P, Smith J, Van der Meeren P . Accurate particle size distribution determination by nanoparticle tracking analysis based on 2-D Brownian dynamics simulation. J Colloid Interface Sci. 2010; 352(2):593-600. DOI: 10.1016/j.jcis.2010.09.006. View

Pohlmann A, Fonseca F, Paese K, Detoni C, Coradini K, Beck R . Poly(ϵ-caprolactone) microcapsules and nanocapsules in drug delivery. Expert Opin Drug Deliv. 2013; 10(5):623-38. DOI: 10.1517/17425247.2013.769956. View

10.

Youm I, Murowchick J, Youan B . Entrapment and release kinetics of furosemide from pegylated nanocarriers. Colloids Surf B Biointerfaces. 2012; 94:133-42. DOI: 10.1016/j.colsurfb.2012.01.027. View

11.

Zimmermann E, Muller R . Electrolyte- and pH-stabilities of aqueous solid lipid nanoparticle (SLN) dispersions in artificial gastrointestinal media. Eur J Pharm Biopharm. 2001; 52(2):203-10. DOI: 10.1016/s0939-6411(01)00167-9. View

12.

Choi W, Lee J, Kim J, Heo S, Jeong Y, Kim Y . Targeted antitumor efficacy and imaging via multifunctional nano-carrier conjugated with anti-HER2 trastuzumab. Nanomedicine. 2014; 11(2):359-68. DOI: 10.1016/j.nano.2014.09.009. View

13.

Kim Y, Fluckiger L, Hoffman M, Lartaud-Idjouadiene I, Atkinson J, Maincent P . The antihypertensive effect of orally administered nifedipine-loaded nanoparticles in spontaneously hypertensive rats. Br J Pharmacol. 1997; 120(3):399-404. PMC: 1564474. DOI: 10.1038/sj.bjp.0700910. View

14.

Oliveira C, Prado W, Lavayen V, Buttenbender S, Beckenkamp A, Martins B . Bromelain-Functionalized Multiple-Wall Lipid-Core Nanocapsules: Formulation, Chemical Structure and Antiproliferative Effect Against Human Breast Cancer Cells (MCF-7). Pharm Res. 2016; 34(2):438-452. DOI: 10.1007/s11095-016-2074-2. View

15.

Ellman G . Tissue sulfhydryl groups. Arch Biochem Biophys. 1959; 82(1):70-7. DOI: 10.1016/0003-9861(59)90090-6. View

16.

Farokhzad O, Cheng J, Teply B, Sherifi I, Jon S, Kantoff P . Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A. 2006; 103(16):6315-20. PMC: 1458875. DOI: 10.1073/pnas.0601755103. View

17.

Liu L, Guo K, Lu J, Venkatraman S, Luo D, Ng K . Biologically active core/shell nanoparticles self-assembled from cholesterol-terminated PEG-TAT for drug delivery across the blood-brain barrier. Biomaterials. 2007; 29(10):1509-17. DOI: 10.1016/j.biomaterials.2007.11.014. View

18.

Li Z, Qiu L, Chen Q, Hao T, Qiao M, Zhao H . pH-sensitive nanoparticles of poly(L-histidine)-poly(lactide-co-glycolide)-tocopheryl polyethylene glycol succinate for anti-tumor drug delivery. Acta Biomater. 2014; 11:137-50. DOI: 10.1016/j.actbio.2014.09.014. View

19.

Alvarez M, Caldiz C, Fantinelli J, Garciarena C, Console G, de Cingolani G . Is cardiac hypertrophy in spontaneously hypertensive rats the cause or the consequence of oxidative stress?. Hypertens Res. 2008; 31(7):1465-76. DOI: 10.1291/hypres.31.1465. View

20.

de Oliveira C, Buttenbender S, Prado W, Beckenkamp A, Asbahr A, Buffon A . Enhanced and Selective Antiproliferative Activity of Methotrexate-Functionalized-Nanocapsules to Human Breast Cancer Cells (MCF-7). Nanomaterials (Basel). 2018; 8(1). PMC: 5791111. DOI: 10.3390/nano8010024. View